Abstract 5653
Background
The efficacy of maintenance chemotherapy (CT) in advanced NSCLC is still under investigation. The multicenter, open label, randomized, phase II MA.NI.LA trial aimed to assess the activity of metronomic oral vinorelbine versus close observation as maintenance treatment following platinum-based CT in patients with advanced NSCLC. Serum angiogenesis biomarkers and the plasma microRNA signature classifier (MSC) associated with tumor aggressiveness in NSCLC patients were here investigated as prognostic and predictive factors.
Methods
119 advanced NSCLC patients with stable disease after platinum-based CT received maintenance metronomic oral vinorelbine (ARM A) or close observation (ARM B). The primary endpoint of the trial was progression free survival (PFS). Plasma samples for biomarkers evaluation were collected at the baseline from all patients. Concentrations of VEGFA and THBS1 were determined using EIA kit (Chemicon International). To determine MSC risk level, custom made microfluidic cards (Thermo Fisher) were adopted to analyze 8 samples simultaneously by RT-qPCR. Cox regression model was used to evaluate the association of biomarkers to PFS and OS.
Results
In the whole cohort, median age was 68.8; M/F: 79/40; stage IIIb/IV:14/105; adeno/other:73/46; PS 0-1/2:113/7. In front of a median follow up of 23.9 months, median PFS was 4.3 and 2.8 months for ARM A and ARM B, respectively (HR = 0.73; 90%CI 0.53-0.999; p = 0.0493). Considering all 119 patients, high VEGFA and THBS1 plasma levels and positive MSC expression were associated with shorter both PFS and OS. HR for 1000 unit, VEGF: 1.56 (90%CI 0.99-2.46; p = 0.054); HR for 10000 unit, THBS1: 1.16 (90%CI 0.97-1.38; p = 0.114); HR for MSC pos vs neg: 1.61 (90%CI 1.05-2.47; p = 0.028). Similar results were obtained considering OS. No interaction between treatment effect and biomarker values were detected.
Conclusions
In advanced NSCLC following platinum-based induction CT, metronomic oral vinorelbine showed a modest, but significant improvement in PFS. In addition, VEGF and MSC could be considered as prognostic but not predictive factors
Clinical trial identification
NCT02176369.
Legal entity responsible for the study
Clips srl.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract